Author(s):
Rohan Ganesh Kamble, Vaishnavi Dattatray Patil, Sipora Sudin Gaikwad
Email(s):
Email ID Not Available
DOI:
10.52711/0975-4385.2025.00044 
Address:
Rohan Ganesh Kamble1, Vaishnavi Dattatray Patil2, Sipora Sudin Gaikwad3
1Student, Genesis College of Pharmacy, Radhanagari, Dist, Kolhapur, Maharashtra.
2Student, Genesis College of Pharmacy, Radhanagari, Dist, Kolhapur, Maharashtra.
3Assistant Professor, Genesis College of Pharmacy, Radhanagari, Dist, Kolhapur, Maharashtra.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2025
ABSTRACT:
Diabetes mellitus is a widespread metabolic condition marked by persistently elevated blood glucose levels due to impaired insulin secretion, action, or a combination of both. The drawbacks and adverse effects associated with conventional synthetic antidiabetic drugs have sparked growing interest in plant-derived therapies. This research focuses on formulating an innovative antidiabetic gummy using leaf extract from Saraca asoca, a plant traditionally recognized for its medicinal properties and known for its inhibitory effects on a-amylase and a-glucosidase enzymes. The gummy formulation incorporates agar as the gelling base, with propylene glycol facilitating extract dispersion and PEG 4000 improving texture and consistency. The finished gummies were assessed for their physical characteristics, pH level, uniformity in weight, and enzymatic inhibition potential. A pH of 3.40 was recorded, indicating favorable conditions for stability and preservative action. In vitro analysis demonstrated substantial inhibition of a-amylase activity (up to 78.81% at 1000µg/mL) and moderate a-glucosidase inhibition (47.20% at the same dose), suggesting the extract's capacity to slow carbohydrate digestion and glucose absorption. The gummy delivery system was selected due to its user-friendly nature, improved patient adherence, and potential as a functional food. Overall, this study supports the potential of Saraca asoca–based gummies as a natural, effective, and accessible option for managing post-meal blood glucose levels, offering promise as both a complementary and preventive strategy in diabetes management.
Cite this article:
Rohan Ganesh Kamble, Vaishnavi Dattatray Patil, Sipora Sudin Gaikwad. Development and Characterization of Saraca asoca Extract Based Gummies Formulation for Antidiabetic Activity. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(4):273-3. doi: 10.52711/0975-4385.2025.00044
Cite(Electronic):
Rohan Ganesh Kamble, Vaishnavi Dattatray Patil, Sipora Sudin Gaikwad. Development and Characterization of Saraca asoca Extract Based Gummies Formulation for Antidiabetic Activity. Research Journal of Pharmacognosy and Phytochemistry. 2025; 17(4):273-3. doi: 10.52711/0975-4385.2025.00044 Available on: https://rjpponline.org/AbstractView.aspx?PID=2025-17-4-4
REFERENCES:
1. Kumudhaveni B, Radha R. Anti-diabetic potential of a traditional polyherbal formulation – a review. Res J Pharm Technol. 2017; 10(6): 1865–9. doi:10.5958/0974-360X.2017.00327.4
2. Misra A, Ramachandran A, Mohan V, Reddy KS. A strategic research framework for defeating diabetes in India: a 21st century agenda. Curr Diab Rep. 2022;22(1):1–9.
3. Medanta. Why Indians are more susceptible to diabetes. 2024 Aug.
4. India Today. India had highest number of diabetics in the world in 2022: Lancet Study. 2024 Nov 14.
5. Firstpost. World Diabetes Day: how India became the world’s ‘capital of untreated diabetics’. 2024 Nov 14.
6. The Times of India. Type-2 diabetes: 46% of patients in India are under 40. 2024 Nov 14.
7. Dayal D, Thukral R, Singh M. Bibliometric analysis of endocrinology, diabetes and metabolism research output from South Asia. Diabetes Metab Syndr. 2023;16(2):102–10.
8. Anjana RM, Deepa M, Pradeepa R, et al. The ICMR–INDIAB study: results from the national study on diabetes in India. Diabetes Metab Syndr. 2022;16(1):102–10.
9. The Times of India. Why are one in four young Indians now affected by type 2 diabetes? 2024 Nov 14.
10. Kumari R, Singh N, Gupta A. Prevalence of type 2 diabetes mellitus (T2DM) in India: a systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(5): 395–403.
11. Dr. Sumaiya. Why Indians are more vulnerable to heart attacks, diabetes, and fatty Liver Disease. 2025 Feb.
12. Saxena R, Mohan V, Ghosh A, et al. Genetic variants and type 2 diabetes in India: a systematic review and meta-analysis. Lancet Reg Health Southeast Asia. 2024;3:100168.
13. India State-Level Disease Burden Initiative Diabetes Collaborators. The increasing burden of diabetes and variations among the states of India: the Global Burden of Disease Study 1990–2016. Lancet Glob Health. 2018;6(12):e1352–62.
14. Boseley S. More than 800 million people around the world have diabetes, study finds. The Guardian. 2024 Nov 13.
15. Financial Times. Diabetics left without treatment as global rate of disease doubles. 2024 Nov 14.
16. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2008; 31(1):1–11.
17. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of once-weekly semaglutide vs. daily insulin glargine in patients with type 2 diabetes. Lancet. 2021; 397(10271): 243–53.
18. Ahuja NK, et al. Recent advancements in oral insulin formulation. J Diabetes Sci Technol. 2021; 15(1):22–30.
19. Raskin P, et al. Afrezza: an inhaled insulin for the treatment of diabetes. Diabetes Ther. 2015; 6(1): 1–14.
20. Kovatchev BP, et al. Artificial pancreas systems: an overview. J Diabetes Sci Technol. 2015;9(5):1012–22.
21. Chen Y, et al. Microneedles for insulin delivery: a review of current research. Ther Deliv. 2020;11(6):343–55.
22. Miele A, et al. Closed-loop artificial pancreas systems: current status and future directions. Diabetes Care. 2019; 42(4): 621–9.
23. Shapiro AMJ, et al. Islet cell transplantation for type 1 diabetes. N Engl J Med. 2000; 343(5): 318–22.
24. Guo X, et al. Stem cell-based therapy for type 1 diabetes: an update. Stem Cell Rev Rep. 2020; 16(5):1095–105.
25. Zayed H, et al. Gene therapy for diabetes: advances and challenges. Nat Rev Endocrinol. 2017;13(6): 345–53.
26. Gonen O, et al. Glucose-responsive insulin: a new approach in diabetes treatment. Endocrinol Metab Clin North Am. 2019; 48(4): 711–20.
27. Dhanani T, Shah S, Kumar S. Flavonoids: a review on plant sources, bioactivities and extraction methods. Ind Crops Prod. 2017; 87: 169–79.
28. Saha S, Verma RJ. Antioxidant activity of polyphenolic extracts of Saraca asoca bark and flowers: a comparative analysis. J Pharm Res. 2011; 4(12): 4603–5.
29. Kumar A, Ilavarasan R, Jayachandran T, et al. Phytochemical investigation on a tropical plant–Saraca indica Linn. Res J Pharm Biol Chem Sci. 2009; 1(1): 49–57.
30. Kumar D, Kumar S, Raj B, Khatri R, Lather A, Hooda T. Anti-diabetic and wound healing potential of plant Saraca asoca leaves in various diabetic animal models. Res J Pharm Technol. 2024;17(10): 4685–93. doi:10.52711/0974-360X.2024.0072.
31. Choudhary RK, Swarnkar PL. Phytochemical and pharmacological potential of Saraca asoca: a review. Int J Pharm Life Sci. 2011;2(7): 962–7.
32. Rathod CP, Ghante MH. Pharmacological importance of Saraca asoca: a review. Res J Pharmacogn Phytochem. 2021; 13(3): 131–5. doi:10.52711/0975-4385.2021.00022
33. Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Boca Raton: CRC Press; 2001.
34. Saravanan R, Prasad NR, Pugalendi KV. Effect of S. asoca bark extract on blood glucose and antioxidant status in streptozotocin diabetic rats. Biol Pharm Bull. 2006; 29(5): 1007–11.
35. Zhang Y, Zhang L, Zhang Y. Oxidative stress in type 2 diabetes: impacts from pathogenesis to therapeutic strategies. Oxid Med Cell Longev. 2023;2023:10453126.
36. Li X, Fang P. Oxidative stress and inflammation in diabetic nephropathy. Front Endocrinol. 2023;14: 10401049.
37. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and β-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009; 5(4): 219–27.
38. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011; 11(2): 98–107.
39. Jain A, Jasmine SS, Saini V. Hypolipidemic, hypoglycemic and antioxidant potential of Saraca asoca ethanolic leaves extract in streptozotocin induced-experimental diabetes. Int J Pharm Pharm Sci. 2013;5(1): 302–5.
40. Thilagam E, Parimaladevi B, Kumarappan C. Anti-hyperglycemic and hypolipidemic effects of Saraca asoca (Roxb.) wild flowers in alloxan-treated diabetic rats. J Pharm Pharmacogn Res. 2013; 1(1): 58–66.
41. Mamatha MK, Suma US, Annegowda HV. The ascent of polyherbal formulation in the treatment of diabetes mellitus. Res J Pharmacogn Phytochem. 2020; 12(4): 256–60. doi:10.5958/0975-4385.2020.00042.4
42. Tundis R, Loizzo M, Menichini F. Natural products as α-amylase and α-glucosidase inhibitors and their hypoglycaemic potential in the treatment of diabetes: an update. Mini Rev Med Chem. 2010; 10(4): 315–31.
43. Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol. 2003; 17(1).
44. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem. 2004; 279(41): 42351–4.
45. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3): 150–9.
46. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab. 2007; 3(1): 46–56.
47. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2): 98–107.
48. Esser N, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2): 141–50.
49. Himalaya Wellness. Ashokarishta – benefits, uses, and ingredients [Internet]. [cited 2025 Apr 30]. Available from: https://www.himalayawellness.in/
50. Kerala Ayurveda. Ashok Ghrita – classical formulation for women's health [Internet]. [cited 2025 Apr 30]. Available from: https://www.keralaayurveda.biz/
51. Mehta D, Kuksal K, Sharma A, et al. Postharvest integration of prickly pear betalain-enriched gummies with different sugar substitutes for decoding diabetes type-II and skin resilience – in vitro and in silico study. Food Chem. 2025; 464: 141612.
52. Saifi A, Chauhan R, Dwivedi J. Development of a polyherbal formulation FMST and evaluation for antidiabetic activity in alloxan induced diabetic rats. Asian J Pharm Res. 2017; 7(1): 1–7.
53. Sharma A, Pal P, Sarkar BR, Mohanty JP, Bhutia S. Preparation, standardisation and evaluation of hypoglycaemic effect of herbal formulation containing five ethnomedicinal plants in alloxan-induced hyperglycemic Wistar rats. Res J Pharm Technol. 2020;13(12):5987–92. doi:10.5958/0974-360X.2020.01044.6
54. Vigil-Cuate LK, Avila-Reyes SV, Camacho-Díaz BH, et al. Effect of agavins and agave syrup use in the formulation of a synbiotic gelatin gummy with microcapsules of Saccharomyces boulardii. Gels. 2024; 10(5).
55. Pal RS, Saraswat N, Wal P, Wal A, Pal Y, Maurya D. Pharmacognostic assessment and quality standards of Saraca asoca and Asparagus racemosus. Res J Pharm Technol. 2021; 14(2): 949–54. doi:10.5958/0974-360X.2021.00169.4
56. 4.Semwal P, Kapoor T, Singh RV. Comparative phytochemical screening of six different plant species of Uttarakhand region. Asian J Pharm Tech. 2014; 4(2): 50–2.
57. Patil SJ, Patil SD, Patil PB, Patil PS, Vambhurkar GB, Raut ID. Evaluation of standardization parameters of Ayurvedic marketed polyherbal formulation. Asian J Pharm Ana. 2018; 8(4): 220–6.
58. Dharamdasani L, Pathan S, Bodhankar P, et al. Synthesis of silver nanoparticle from Saraca asoca leaf extract and study of its antibacterial and antioxidant activity. Int J Health Sci Res. 7: 342–50.
59. Shivhare B, Solanki R, Pandey M, Kumar R. Antioxidant capacity and metabolic characterization of aqueous and ethanolic extraction of Saraca indica. J Pharmacogn Phytochem. 2023; 12: 44–51.
60. Ashwini L, Nidhya G, Latha S, Chamundeeswari D. Comparison of herbal formulation and herbal extracts of seeds and fruits of selected medicinal plants for antidiabetic enzyme inhibitory studies. Res J Pharm Technol. 2022; 15(10): 4789–94. doi:10.52711/0974-360X.2022.00804